Option chain shows key data for Shapeways Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Shapeways Holdings.

Shapeways Holdings (OTC:SHPSQ) Stock, Option Chain

Shapeways Holdings Inc is a leading digital manufacturer combining high quality, flexible on-demand manufacturing with purpose-built proprietary software to offer customers an end-to-end digital manufacturing platform on which they can rapidly transform digital designs into physical products. It makes industrial-grade additive manufacturing accessible by fully digitizing the end-to-end manufacturing process. The Company reports in one segment, which focuses on providing additive manufacturing services to customers.

Shapeways Holdings Inc Warrants (31/10/2026)

Shapeways Holdings Inc

News

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Says Its ART100 Systems Have Been Delivered To Glo-Med Networks And Are Preparing For Deployment At A US Hospital

Ormat Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORA#NYSE">ORA</a>), a leading geothermal and renewable energy company, today announced the signing of a 10-year Power Purchase Agreement (PPA) with Calpine Energy Solutions, one of North America's largest energy suppliers. Under this agreement, Calpine Energy Solutions will purchase up to 15 megawatts (MW) of clean, renewable energy from the Mammoth 2 geothermal power plant located near Mammoth Lakes, California, to support demand within its retail portfolio.
Energy deliveries under the PPA are set to begin in the first quarter of 2027 and will replace the existing PPA with the Southern California Edison Company (SCE). Notably, the new PPA, which includes an increase in production capacity and a higher price point, highlights the tight supply-demand balance of carbon-differentiated electricity in California, driven by state Renewable Portfolio Standards (RPS) compliance needs and voluntary corporate demand.

Ormat Technologies Announces 10-Year PPA With Calpine Energy Solutions For Up To 15MW From Mammoth 2 Geothermal Plant Starting Q1 2027; Replacing Southern California Edison Deal, Reflecting California's Carbon-Differentiated Electricity Demand

The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) reported upbeat fourth-quarter results on Tuesday.
Revenue rose 20% year over year to $5.33 billion, beating the consensus of $5.19 billion.
Net interest revenue rose 19% Y/Y to $2.531 billion in the fourth quarter. Clients' daily average trades totaled 6.312 million, up 22% Y/Y.
Adjusted net income rose 44% Y/Y to $1.97 billion. Adjusted EPS increased 49% to $1.01, beating the consensus of $0.91.
Total client assets rose 19% Y/Y to $10.10trillion. The company's active brokerage accounts reached 36.5 million in the quarter.
Mike Verdeschi, CFO, said, "Client transactional sweep cash grew by $35 billion versus 3Q24, including a $25 billion increase in December due to typical year-end seasonality. This build helped us further reduce Bank Supplemental Funding by $14.9 billion to $49.9 billion – down ~50% from peak levels."
Charles Schwab shares gained 5.9% to close at $80.93 on Tuesday.
These analysts made changes to their price targets on Charles Schwab following earnings announcement.
<ul>
<li>Wells Fargo analyst Michael Brown upgraded Charles Schwab from Equal-Weight to Overweight and raised the price target from $89 to $93.</li>
<li>Barclays analyst Benjamin Budish maintained the stock with an Overweight and raised the price target from $95 to $96.</li>
<li>Citigroup analyst Christopher Allen maintained Charles Schwab with a Neutral and raised the price target from $80 to $85.</li>
<li>Deutsche Bank analyst Brian Bedell maintained Charles Schwab with a Buy and boosted the price target from $98 to $105.</li>
</ul>
Considering buying SCHW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="492" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154-1024x492.png" alt="" class="wp-image-744746" style="width:530px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154-1024x492.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154-300x144.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154-768x369.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43123084/top-3-health-care-stocks-that-could-blast-off-this-quarter">Top 3 Health Care Stocks That Could Blast Off This Quarter</a></li>
</ul>

Earnings

Price Target

Markets

Analyst Ratings

Trading Ideas

SCHW

Charles Schwab Analysts Increase Their Forecasts After Upbeat Results

BDMD

Baird Medical Investment Holdings Is Expanding Its Presence Into San Francisco

<h3 class="wp-block-heading">Tech Stocks In Focus</h3>
On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) is a quantum stock. &#8220;If you want to participate in a short squeeze, this is better <a href="https://www.benzinga.com/quote/RGTI">than most,&#8221; he added</a>.
Shares of quantum stocks, including Rigetti Computing, rose sharply on Tuesday amid strength in tech and AI stocks as investors assessed the new administration&#8217;s policies and AI efforts.
Cramer recommended buying ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>), adding that it is a &#8220;remarkably great&#8221; company.
Supporting his view, Wells Fargo analyst Joseph Quatrochi, on Jan. 13, maintained ASML with an Overweight and raised the price target from $790 to $860.
Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) is a &#8220;great&#8221; company, Cramer said. &#8220;I do think that there's a lot of people who believe that they will not be able to deliver on this quarter. I, therefore, am reluctant to get in ahead of the quarter.&#8221;
AMD will report fiscal fourth quarter and full year 2024 financial results after the closing bell on Tuesday, Feb. 4. Analysts expect the company to report quarterly earnings at $1.09 per share, up from 77 cents per share in the year-ago period.
<h3 class="wp-block-heading">Hold On To This Stock</h3>
The &#8220;Mad Money&#8221; host recommended to hold on to Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>). &#8220;I don't want to sell it here, we might be at some sort of trough at this very moment in Dow pricing,&#8221; he added.
Recently, on Jan. 13, Morgan Stanley analyst Vincent Andrews also maintained Dow with an Equal-Weight rating and cut the price target from $59 to $46.
<h3 class="wp-block-heading">Discusses His View On Health Care Stocks</h3>
Cramer said Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) is not his favorite and considers Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) as the better bet for this group.
Adding support to Cramer's view, Stifel analyst Jonathan Block, on Jan. 7, lowered the price target on the stock from $20 to $18.
Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) is losing a lot of money and is &#8220;just a total spec,&#8221; Cramer said.
On Nov. 6, Clover Health Investments reported worse-than-expected third-quarter revenue results.
Price Action:
<ul>
<li>Rigetti Computing shares jumped 42.2% to settle at $13.98 on Tuesday.</li>
<li>ASML shares gained 0.9% to close at $763.00 during the session.</li>
<li>AMD shares gained 0.7% to close at $122.28.</li>
<li>Dow shares gained 1.3% to settle at $41.58 on Tuesday.</li>
<li>Elanco Animal Health shares gained 0.2% to close at $12.04.</li>
<li>Clover Health Investments shares rose 3.9% to settle at $4.24 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Tech

Media

ASML

CHWY

CLOV

ELAN

RGTI

Jim Cramer: AMD Is A 'Great' Company, Hold Onto Dow Inc.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Feqs-cockpit.com%2Fcgi-bin%2Ffncls.ssp%3Ffn%3Dredirect%26url%3D5a17290acfd416e9e07b3d92a8056cf5%26application_id%3D1862413%26site_id%3Dairport_aws%26application_name%3Dnews&amp;esheet=54185193&amp;newsitemid=20250122434451&amp;lan=en-US&amp;anchor=Teradyne+Robotics&amp;index=1&amp;md5=66f9217e1043b5d0e28297d01da918dd">Teradyne Robotics</a>, a division of Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) and global leader in advanced robotics solutions, and Analog Devices, Inc. (ADI), a global semiconductor leader, today announced a strategic partnership aimed at accelerating the development and usage of advanced robotics.
Teradyne Robotics, which includes Universal Robots (UR) and Mobile Industrial Robots (MiR), will partner with ADI to develop and deploy robots, AI and software in support of ADI's collaborative automation initiative, which aims to enhance safety, efficiency and optimize fabrication and backend operations through automation. These solutions will address key challenges facing the semiconductor market, including ergonomic issues due to highly repetitive tasks, manufacturing downtime, insufficient workforce, and real estate constraints.

Teradyne Robotics Partners With Analog Devices To Accelerate Advanced Robotics Development For Semiconductor Market

WIIM

QBTS

D-Wave Quantum shares are trading higher after the company revealed a new program to fast-track the deployment of quantum computing applications.

MGTX

MeiraGTx Granted FDA Rare Pediatric Disease Designation For AAV8-RK-RetGC In Leber Congenital Amaurosis Due To GUCY2D Mutations

Prominent Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) critic Peter Schiff reignited debates on the crypto king&#8217;s legitimacy by labeling it a meme coin <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43123173/3-reasons-why-bitcoin-could-hit-122000-soon-10x-research">devoid of intrinsic value</a>.
What Happened: Schiff on Tuesday on X <a href="https://x.com/PeterSchiff/status/1881783737584906551">responded</a> to Anthony Pompliano's explanation of meme coins, stating that there's little to distinguish Bitcoin from newer meme assets like TRUMP.
"It's a fine line to walk when explaining a meme coin without exposing the same fraud about Bitcoin," he added. He <a href="https://x.com/PeterSchiff/status/1881770557223682309">stated</a>, "Bitcoin is a meme coin."
Schiff's post sparked debate across Crypto Twitter, with some comparing Bitcoin to gold. 
Bitcoin podcast host Walker argued, "The meme is perfected sound money that is superior to gold" and claimed Bitcoin is gradually <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42935597/mark-cuban-advocates-bitcoin-over-gold-during-economic-turmoil-i-think-it-has-more-value-than-gold">demonetizing gold</a>.
CryptoQuant CEO Ki Young Ju took it further, calling gold a "meme asset," with 90% of its valuation stemming from narrative belief. 
He concluded, "Goldbugs are no different from Bitcoin maxis."
Schiff dismissed the comparisons, reiterating that gold's value is rooted in tangible properties, unlike Bitcoin, which he called &#8220;fool&#8217;s gold.&#8221;
Schiff's detractors reminded him of past predictions, including his claim that Bitcoin would never reach $100,000, and asked what he would say if it hit $1 million. 
One trader quipped, "Peter Schiff wouldn't exist without Bitcoin," to which Schiff retorted that he was well-known before Bitcoin.
Also Read: <a href="https://www.benzinga.com/25/01/43078360/peter-schiff-gets-sarcastic-wonders-whether-biden-will-sell-some-bitcoin-on-last-day-of-presidency">Peter Schiff Says &#8216;Last Night&#8217; For Biden To Sell Some Bitcoin Before Trump Takes Over: &#8216;Let&#8217;s See If He Takes Advantage Of The Opportunity&#8217;</a>
Why It Matters: Schiff has consistently expressed concern over what he perceives as a <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42878139/peter-schiff-doesnt-hate-bitcoin-but-warns-millions-will-lose-more-than-they-can-afford-in-speculative-mania">speculative mania surrounding cryptocurrencies</a>, warning it could harm the principles of sound money. 
While he insists he doesn't hate Bitcoin, he cautioned that millions might lose more than they can afford.
In December 2024, Schiff argued <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42392610/peter-schiff-bitcoin-is-a-threat-to-the-us-and-public-enemy-number-one">Bitcoin could become a "public enemy"</a> if the government squandered taxpayer money on it, describing it as the riskiest asset.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43123173/3-reasons-why-bitcoin-could-hit-122000-soon-10x-research">3 Reasons Why Bitcoin Could Hit $122,000 Soon: 10x Research</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

'Bitcoin Is A Meme Coin' Says Peter Schiff, Critics Clap Back: 'Goldbugs Are No Different From Bitcoin Maxis'

<a href="https://www.globenewswire.com/Tracker?data=T8uscBjMZ3PQs7RRv2I2QhSiQsH6XlJSkrW74rd7kj9oDlKXDlgfEjAs624j5QKkV1AQbadb2wEypzjTMzs-z2dzt7eErpuowSFIrPM8c5A=">Scorpius Holdings, Inc</a> (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced its collaboration with KaloCyte, a pioneering pre-clinical company in the field of therapeutic innovation. Under this initial project, Scorpius will utilize its scientific and technical expertise to enhance manufacturing efficiencies for KaloCyte's lead candidate, ErythroMer&#x2122;, a dried, bio-inspired artificial red blood cell designed to address life-threatening blood loss in situations where stored red blood cells are unavailable, unsuitable, or in short supply. The two companies are also evaluating opportunities to establish a commercial-scale manufacturing agreement.

Biotech

General

SCPX

Scorpius Announces Collaboration With KaloCyte To Enhance Manufacturing For ErythroMer, Evaluating Commercial-Scale Manufacturing Agreement

Oppenheimer analyst Brian Schwartz maintains Agilysys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) with a Outperform and lowers the price target from $150 to $135.

AGYS

Oppenheimer Maintains Outperform on Agilysys, Lowers Price Target to $135

Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO). This application, focused on its lead asset SPC-15, highlights Silo's commitment to advancing treatments for stress-induced psychiatric disorders, including post-traumatic stress disorder (PTSD).
The provisional patent covers the chronic, combinatorial targeting of N-methyl-D-aspartate receptors (NMDARs) and serotonin type IV receptors (5-HT4Rs) to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia. This filing adds to Silo's growing portfolio of pending patents for SPC-15 technology, originally licensed through a collaboration with Columbia University. This exclusive agreement enables Silo to develop, manufacture, and commercialize SPC-15 globally.

SILO

Silo Pharma Announces Provisional Patent Filing For SPC-15 Targeting NMDARs And 5-HT4Rs For Stress-Induced Psychiatric Disorders; Advances Collaboration With Columbia University

C3.Ai shares are trading higher after the company announced a partnership with McKinsey to drive rapid and scalable AI solutions for global enterprises.

Morgan Stanley analyst Devin McDermott downgrades Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) from Equal-Weight to Underweight and announces $37 price target.

Downgrades

Morgan Stanley Downgrades Murphy Oil to Underweight, Announces $37 Price Target

Earnings Beats

HDFC Bank Q3 EPS $0.82, Sales $7.73B Down From $8.62B YoY

Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) just got its <a href="https://www.benzinga.com/topic/artificial-intelligence">golden AI ticket</a>. The stock surged as much as 8.51% in pre-market trading Wednesday after President Donald Trump unveiled Project Stargate, a massive $500 billion AI infrastructure initiative featuring Oracle, OpenAI, Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and SoftBank Capital.
With $100 billion committed in the first year alone, this project cements Oracle's role as a key AI backbone. But is this just a short-term pop, or does it signal a deeper bull case for Oracle stock?
<h2 class="wp-block-heading">Oracle's AI Advantage Just Got Supercharged</h2>
Oracle has been aggressively expanding its AI and cloud offerings, positioning itself as a critical infrastructure provider for generative AI workloads. Project Stargate validates that strategy, giving Oracle direct government-backed investment and integration with AI giants like OpenAI.
For investors, this means Oracle is no longer just competing in the AI arms race—it's helping build the battlefield. Expect increased cloud demand, long-term government contracts, and a higher revenue ceiling.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/01/43121798/elon-musk-says-project-stargate-doesnt-actually-have-the-money-after-trump-announces-500-billion-ai-investment-led-by-softbank-oracle-and-openai">Elon Musk Says Project Stargate Doesn&#8217;t &#8216;Actually Have The Money&#8217; After Trump Announces $500 Billion AI Investment Led By SoftBank, Oracle And OpenAI</a>
<h2 class="wp-block-heading">Ellison's Billionaire Flex: Confidence In Oracle's Future</h2>
Oracle&#8217;s CEO Larry Ellison's $12 billion windfall from the stock surge speaks volumes. His 41% stake in Oracle makes him the biggest beneficiary of this AI momentum, and the fact that he <a href="https://www.forbes.com/sites/dereksaul/2025/01/21/oracle-stock-surges-ahead-of-500-billion-stargate-openai-trump-deal/">overtook</a> Meta Platforms Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg to become the world's third-richest person highlights just how much value the market sees in Oracle's future. 
When insiders win big, long-term investors take notice.
<h2 class="wp-block-heading">ORCL Stock Chart: The Bullish Case</h2>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="638" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22073338/Screenshot-2025-01-22-at-5.55.52-PM.png" alt="" class="wp-image-744604" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22073338/Screenshot-2025-01-22-at-5.55.52-PM.png 638w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22073338/Screenshot-2025-01-22-at-5.55.52-PM-300x232.png 300w" sizes="(max-width: 638px) 100vw, 638px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
ORCL stock is trading above its eight, 20 and 200-day simple moving averages, signaling strong buying pressure. While the 50-day moving average sits slightly higher at $176.33 (vs. ORCL stock at $172.57), the broader trend remains bullish. 
The RSI (relative strength index) at 57.50 suggests room to run before hitting overbought levels. Although, the MACD (moving average convergence/divergence) indicator at a negative 3.72, signals bearish momentum.
<h2 class="wp-block-heading">Investor Takeaway: More Than Just A Hype Rally</h2>
AI narratives have driven short-term pops before, but Project Stargate gives Oracle something tangible—a direct capital infusion, AI partnerships, and potential long-term infrastructure dominance.
With strong technicals and institutional backing, ORCL stock's momentum could be more than just a momentary surge. Investors betting on the AI boom now have a compelling reason to keep Oracle on their radar.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/43122667/oracle-unveils-ai-powered-sales-tools-to-boost-customer-engagements-details">Oracle Unveils AI-Powered Sales Tools To Boost Customer Engagements: Details</a></li>
</ul>
Photo: Shutterstock

Technicals

NVDA

ORCL

Oracle's AI Moonshot: Why Project Stargate Could Propel ORCL Stock Higher

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/01/21/final-trades-disney-affiliated-managers-unitedhealth-and-block.html">Halftime Report Final Trades</a>,&#8221; Joseph M. Terranova of Virtus Investment Partners picked Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>).
Adding support to his choice, Wells Fargo analyst Andrew Bauch, on Jan. 16, maintained Block with an Overweight rating and raised the price target from $85 to $95.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>.
Joshua Brown of Ritholtz Wealth Management named The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) as <a href="https://www.benzinga.com/25/01/42890512/disney-now-has-157-million-monthly-ad-supported-viewers-on-disney-hulu-and-espn-globally">his final trade</a>.
In recent news, on Jan. 8, Walt Disney said that its streaming platforms have reached another milestone. The company&#8217;s streaming platforms, Disney+, Hulu, and ESPN+, have amassed approximately 157 million monthly active users globally who engage with ad-supported content.
In the healthcare sector, Stephanie Link of Hightower said she likes UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) at 17 times earnings and long-term average is 24 times. &#8220;I like the discount,&#8221; she added.
In recent earnings news, UnitedHealth Group, last week, reported better-than-expected fourth-quarter earnings and reaffirmed 2025 guidance. The company reported adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.
Rounding out the trades, Brian Belski of BMO Capital Markets picked Affiliated Managers Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>), a financial stock.
Supporting his view, Deutsche Bank analyst Brian Bedell, on Nov. 11, maintained Affiliated Managers Group with a Buy rating and raised the price target from $204 to $208.
Price Action:
<ul>
<li>Disney shares gained 1.6% to close at $108.70 during Tuesday's session.</li>
<li>Affiliated Managers Group gained 0.9% to settle at $188.73 on Tuesday.</li>
<li>UnitedHealth gained 3% to close at $524.99 on Tuesday.</li>
<li>Block shares rose 2.9% to close at $89.50.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>
Image: Shutterstock

Block, Disney, Affiliated Managers Group And A Health Care Stock On CNBC's 'Final Trades'

KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) reported better-than-expected earnings for the <a href="https://www.benzinga.com/quote/KEY/earnings">fourth quarter on Tuesday</a>.
The company posted quarterly earnings of 38 cents per share which beat the analyst consensus estimate of 33 cents per share. The company's quarterly sales came in at $865.00 million.
Chairman and CEO, Chris Gorman said, &#8220;Our strong financial results are a function of continued client momentum. Relationship households were up 3%, client deposits were up 4%, and AUM increased to a record level of $61 billion in 2024. We continued to drive significant progress in each of our strategic, fee-based businesses – wealth management, commercial payments, and investment banking.
I am very proud of all that our team accomplished in 2024. As we turn the page to 2025, we celebrate KeyBank&#8217;s 200th anniversary, a remarkable milestone that reflects the hard work of our teammates over the past two centuries, and their collective dedication to our clients. With strong performance momentum and a leading capital position, we are well positioned for sound, profitable growth in 2025 and beyond.&#8221;
KeyCorp shares fell 3.6% to close at $17.64 on Tuesday.
These analysts made changes to their price targets on KeyCorp following earnings announcement.
<ul>
<li>Morgan Stanley analyst Manan Gosalia maintained KeyCorp with an Equal-Weight and lowered the price target from $23 to $22.</li>
<li>Keefe, Bruyette &amp; Woods analyst David Konrad maintained the stock with an Outperform and lowered the price target from $22 to $21.</li>
</ul>
Considering buying KEY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22082545/image-153-1024x504.png" alt="" class="wp-image-744719" style="width:559px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22082545/image-153-1024x504.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22082545/image-153-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22082545/image-153-768x378.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22082545/image-153.png 1142w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43123084/top-3-health-care-stocks-that-could-blast-off-this-quarter">Top 3 Health Care Stocks That Could Blast Off This Quarter</a></li>
</ul>

KeyCorp Analysts Slash Their Forecasts After Q4 Results

NTRA

Natera shares are trading higher after the company announced it will reveal new insights and innovations for tissue-free MRD at ASCO GI 2025

Morgan Stanley analyst Keith Weiss maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Overweight and lowers the price target from $548 to $540.

Comments

Shapeways Holdings

Shapeways Holdings (SHPSQ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga